web analytics

Why Decision Diagnostics Corp (OTCMKTS: DECN) Holds the Cards

0

Decision Diagnostics Corp (OTCMKTS: DECN) saw another fast move after the Company said it has finalized the configuration of the GenViro! Swift Kit test strip that will go into production just as soon as the FDA grants emergency status to the DECN product through its advanced development team in Korea. The company’s methodology employs a simple, easy to use, swift (15 seconds and faster than Rapid) method for determining the presence of a virus in blood lyced into blood plasma. Blood sample requirements are 1-2 microliters. The kits will be manufactured for DECN in Korea by its contract manufacturer, the same company that manufactures our diabetic test strips. While the manufacturing will occur in Korea, the test strip is 100% of American design.

DECN has seen a huge rise in recent weeks as it unveils its new GenViro(TM) Corona Virus Screening Kit. What sets the GenViro covid test above the rest is it “provides results in 15 seconds, based on a small finger prick blood sample.” according to DECN management. Microcapdaily was there at the beginning reporting on March 3:  DECN is on a fast rise after the Company announced its new screening methodology for the Coronavirus (Covid19). According to DECN the product is timely, simple to use, cost effective and will be commercial ready in the summer of 2020. This is big news for DECN whose stock price had been falling steadily from over $0.09 last March recently hitting lows of $0.01. DECN popped to $0.04 on the news and looked set to top over $100k in dollar volume yesterday.

Decision Diagnostics Corp. (OTC PINK:DECN) bills itself as an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! (“Sunshine”) diabetes test strip, its GenAccord! Enhance (“Caterpillar”) strip and meter systems for the uninsured and under-insured, its GenChoice! (“Ladybug”) test strip now in the later stages of FDA 510(k) prosecution, and its GenUltimate! Precis products manufactured for International markets.

Recently the Company unveiled its test for the coronavirus (COVID19). DECN management said at the time: “we present the Coronavirus test kit and the Phase 1 unit forecast. The introduction of our new screening methodology for the Coronavirus (Covid19) will provide a timely, simple to use and cost effective solution for the screening of the frightening COVID19 virus. First uses of our kits will be in pharmacies, doctor’s offices, clinics and urgent care centers, and long term care facilities. We anticipate the sale of 420,000,000 kits in the first full year of commercial sale. The company has retained FDA counsel who is in the process of securing expected emergency waiver for diagnostics and diagnostic devices.”

To Find out the inside Scoop on DECN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DECN

On March 23 DECN reported the company, through its advanced development team in Korea, have finalized the configuration of the GenViro! Swift Kit test strip that will go into production just as soon as the FDA grants emergency status to the DECN product. The company’s methodology employs a simple, easy to use, swift (15 seconds and faster than Rapid) method for determining the presence of a virus in blood lyced into blood plasma. Blood sample requirements are 1-2 microliters. The kits will be manufactured for DECN in Korea by its contract manufacturer, the same company that manufactures our diabetic test strips. While the manufacturing will occur in Korea, the test strip is 100% of American design.

Keith Berman, CEO of DECN commented, “The news channels are filled with talk about the coming rapid test kits for the detection of the virus Covid-19. These kits are recent creations based on traditional chemistry methods such as anti-body/antigen analysis or PCR (the nose swab RNA method). While these methods offer a path to results, we have not found any that will give a patient a result in less than minutes (and we have our doubts), or are methods that can provide on the spot analysis. Further these methods and variations of same, typically require analyzers that are in the instrument arsenals of large hospitals or large commercial laboratories, not the shopping center parking lot or the flu shot clinic at the local pharmacy, or the meeting hall at a church. GenViro! provides results in 15 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19. Our method is quicker, provides the desired result, is much cheaper, and effective.”

 

We have a Monster Pick Coming. Subscribe Right Now!

Currenly trading at a $21 million market valuation DECN is an exciting story in small caps establishing itself as a volume leader and proven runner in recent weeks. DECN new GenViro(TM) Corona Virus Screening Kit easily tops anything on the market as it provides results in 15 seconds, based on a small finger prick blood sample according to the Company.  CEO Keith Berman who said the other day “GenViro! provides results in 15 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19. Our method is quicker, provides the desired result, is much cheaper, and effective.” We will be updating on DECN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DECN.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in DECN either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.